ENTA Stock Price
Enanta Pharmaceuticals, Inc.
ENTA stock price is $12.10 (-2.18% on the day), giving Enanta Pharmaceuticals, Inc. a market cap of $360.28M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ENTA Stock Overview
- Price
- $12.10
- Previous close
- $12.37
- Open
- $12.26
- Market cap
- $360.28M
- P/E ratio
- -4.4
- 52-week range
- $10.20 - $17.15
- 1-year price target
- $19.83
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 39
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENTA | $12.10 | -2.2% | 282.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enanta Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW